Maruyama Y, Kryscio R, van Nagell J R, Yoneda J, Donaldson E, Hanson M, Beach J L, Feola J M, Martin A, Parker C
Lancet. 1985 May 18;1(8438):1120-2. doi: 10.1016/s0140-6736(85)92430-4.
Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cf intracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.
锎 - 252（²⁵²Cf）是一种发射快中子的放射性同位素，被用于对82例晚期（III期和IV期）宫颈癌患者进行中子近距离治疗（NT）。将结果与铯 - 137近距离治疗进行比较；两种同位素均与高剂量分割盆腔放疗联合使用。在IIIB期疾病（即肿瘤侵犯至盆腔侧壁）患者中，²⁵²Cf腔内治疗的5年生存率为54%，而铯组为12%。为达到有效治疗，Cf - NT必须在体外束（光子）治疗之前进行。
